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The two-pore potassium channel, TRESK has been implicated in nociception and pain disorders. We have for the ﬁrst time
investigated TRESK function in human nociceptive neurons using induced pluripotent stem cell-based models. Nociceptors from
migraine patients with the F139WfsX2 mutation show loss of functional TRESK at the membrane, with a corresponding signiﬁ-
cant increase in neuronal excitability. Furthermore, using CRISPR-Cas9 engineering to correct the F139WfsX2 mutation, we show
a reversal of the heightened neuronal excitability, linking the phenotype to the mutation. In contrast we ﬁnd no change in
excitability in induced pluripotent stem cell derived nociceptors with the C110R mutation and preserved TRESK current; thereby
conﬁrming that only the frameshift mutation is associated with loss of function and a migraine relevant cellular phenotype. We
then demonstrate the importance of TRESK to pain states by showing that the TRESK activator, cloxyquin, can reduce the
spontaneous ﬁring of nociceptors in an in vitro human pain model. Using the chronic nitroglycerine rodent migraine model,
we demonstrate that mice lacking TRESK develop exaggerated nitroglycerine-induced mechanical and thermal hyperalgesia, and
furthermore, show that cloxyquin conversely is able to prevent sensitization. Collectively, our ﬁndings provide evidence for a role
of TRESK in migraine pathogenesis and its suitability as a therapeutic target.
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Introduction
The two-pore domain K+ channel (K2P) family mediate
‘leak’ potassium current, which is a major contributor to
neuronal resting membrane potential and also serves to
counter depolarizing stimuli. TRESK is a K2P channel
with enriched expression in sensory ganglia with several
lines of evidence implicating channel activity in normal
and pathological pain processing. TRESK knockout mouse
models demonstrate increased excitability of sensory ganglia
and behavioural hypersensitivity to noxious and non-nox-
ious sensory stimuli, consistent with an inhibitory effect of
TRESK on neural excitability (Dobler et al., 2007; Weir
et al., 2019). Pharmacological inhibition of TRESK induces
nocifensive behaviours in healthy rats (Tulleuda et al.,
2011). In the context of pathological pain, KCNK18
(TRESK) mRNA is downregulated following nerve injury
and delivery of exogenous TRESK ameliorates pain hyper-
sensitivity following nerve injury, consistent with a crucial
role in neuropathic pain development/maintenance (Tulleuda
et al., 2011; Zhou et al., 2013). This has prompted several
drug discovery efforts, with TRESK activators seen as a
promising strategy for analgesic drug development (Wright
et al., 2013; Bruner et al., 2014). However, a confound of
pursuing drug discovery based on these studies is that
human and mouse TRESK demonstrate signiﬁcant differ-
ences, including low sequence homology and differing pH
sensitivity (Keshavaprasad et al., 2005).
The role of KCNK18, the gene encoding the TRESK K2P
channel, in genetic causation of migraine has been more
controversial. A frameshift mutation, F139WfsX24 in
KCNK18 was originally identiﬁed in one migraine pro-
band, as part of a larger study investigating the role of
brain-expressed ion channel genes in paroxysmal neuro-
logical disorders, wherein 150 ion channel genes were
sequenced in 110 unrelated migraine subjects (Lafreniere
et al., 2010; Lafreniere and Rouleau, 2012). The migraine
proband belonged to a large multi-generation family segre-
gating migraine with aura in an autosomal dominant pat-
tern, and a genome-wide linkage screen in this family
showed signiﬁcant linkage on chromosome 10q25.2-3, a
region harbouring KCNK18 (Lafreniere et al., 2010). The
frameshift mutation, which prematurely truncates TRESK,
furthermore caused a dominant negative loss of TRESK
function of the channel when expressed in Xenopus oo-
cytes. In trigeminal ganglion, TRESK is the dominant
K2P channel (Bautista et al., 2008) and the collective
data were supportive that TRESK may have an important
role in migraine pathogenesis.
However, in further work, sequencing of KCNK18 in
511 sporadic migraine subjects and 505 ethnically-matched
controls revealed ﬁve further missense variants and no
frameshift mutations in this cohort (Andres-Enguix et al.,
2012). Of these missense mutations, only A34V (one mi-
graine proband alone) and C110R (present in migraineurs
and controls) caused a loss of function in Xenopus oocytes.
Furthermore, no other migraine families have been reported
with segregating deleterious mutations in KCNK18; there is
no evidence of genetic association in sporadic migraine and
the ExAC browser identiﬁes a number of potentially dis-
ruptive mutations including frameshift mutations in
KCNK18 (Lek et al., 2016) that are present in the general
population. Overall, despite the genome-wide signiﬁcant
linkage in the originally reported family, the evidence for
a role of gene mutations in KCNK18 in migraine genetic
causation is weak.
We therefore sought to investigate the effects of the
F139WfsX24 mutation on human nociceptor function by
generating induced pluripotent stem cell (iPSC) lines from
three migraine with aura affected female siblings from the
originally described family. This allowed us to study the
functional effects of the mutation in its native cellular
and genetic environment. CRISPR-Cas9 genome engineer-
ing also afforded us the opportunity to correlate cellular
phenotypes to the F139WfsX24 allele. We ﬁnd that
TRESK is expressed in human non-peptidergic nociceptive
neurons differentiated from iPSCs and that the
F139WfsX24 mutation leads to complete loss of TRESK
current with resulting heightened neuronal excitability.
These results are in contrast to the normal excitability
state of C110R iPSC nociceptors, offering insight as to
why the two variants may have differing disease pene-
trance. We then show the potential role of TRESK activa-
tors as a pain and migraine therapeutic by demonstrating
that cloxyquin can ameliorate phenotypes of an in vitro
pain model and the chronic nitroglycerine (GTN) in vivo
migraine model. Our work therefore demonstrates the im-
portance of TRESK in human nociceptor function and in
migraine mechanisms.
Materials and methods
Ethics statement
Induced pluripotent stem cells
The human iPSC lines used for this study were derived from
human skin biopsy ﬁbroblasts and blood erythroblasts, follow-
ing signed informed consent, with approval from the UK NHS
Research Ethics Committee (REC: 13/SC/0179 and 10/H0505/
71) and were derived as part of the IMI-EU sponsored
StemBANCC consortium. Fibroblasts for line SBAD2 and
NHDF1 were purchased from Lonza, who provide the follow-
ing ethics statement: ‘These cells were isolated from donated
human tissue after obtaining permission for their use in research
applications by informed consent or legal authorization’. The
C110R lines were derived from erythroblasts obtained from a
subject recruited in QUT, Australia (HREC: 1400000748).
Animal studies
All procedures were carried out under an approved UK Home
Ofﬁce License, in accordance with the UK Home Ofﬁce
Animals (Scientiﬁc Procedures) Act 1986. Every effort was
made to minimize animal numbers and suffering by adhering
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to the ARRIVE guidelines. Mice were housed in pathogen-free
individually ventilated cages with 12:12-h light/dark cycles and
access to food and water was given ad libitum. Animals were
housed in cages of not more than ﬁve animals, between 2 and
4 months old and weighing 20–30 g over the course of the
testing.
Exome analysis
DNA was prepared for exome sequencing using the Nimblegen
SeqCap EZ Exome v3.0 kit according to the manufacturer’s
instructions. Libraries were sequenced on the Illumina HiSeq
4000 platform, producing 75-bp paired-end reads. The equiva-
lent of 60M 75-bp read-pairs were generated for each
sample. Reads were mapped to the reference genome
(hs37d5) using Stampy and PCR duplicates were removed
using Picard. Variants were called within the bait regions 
50 bp using Platypus and annotated with a number of data-
bases by a combination of Variant Effect Predictor (VEP) and
in-house Python scripts. AVIA v2.0 was used to annotate
sequencing variants (Vuong et al., 2015). Calculation of max-
imum allele frequency of a disease causing variant in migraine
was performed using alleleFrequencyApp (Whifﬁn et al.,
2017), with population prevalence of 1:7, a maximum propor-
tion of Mendelian genetic cases of 10% and a penetrance of 1.
Generation and culture of iPSC lines
In this study, we used nine iPSC-derived lines outlined in
Supplementary Table 1. Newly derived lines were repro-
grammed using the Nakanishi SeVdp vector Sendai system
described previously (Nishimura et al., 2011) or CytoTune
(Life Technologies). Six lines used were derived from skin
biopsies: three healthy controls (AH017, SBAD02, NHDF1)
and three lines from migraine patients (837, 838, 839), three
sisters all belonging to the same family with the F139WfsX24
mutation in KCNK18 gene encoding TRESK. Two additional
lines were reprogrammed from blood erythroblasts; BPC345
(healthy control) and BP8512 (containing the C110R TRESK
variant). A further iPSC line, RCi002-A, which is from a pa-
tient with inherited erythromelalgia and having the F1449V
mutation in SCN9A, was obtained from the EBiSC consortium
and has been published (Cao et al., 2016).
Assessment of genome integrity
Before initiation of differentiation, iPSCs genome integrity was
assessed by an Illumina HumanCytoSNP-12v2.1 beadchip
array (300000 markers) and analysed using KaryoStudio
software (Illumina). Single nucleotide polymorphism (SNP) de-
viations in iPSC lines were compared to parent ﬁbroblast
pools. IiPSC pluripotency was assessed for pluripotency mar-
kers NANOG and OCT-4 by immunocytochemistry.
To conﬁrm genotype identity of iPSC lines, genomic DNA was
isolated from patient and control iPSC’s and polymerase chain
reaction (PCR) was performed with primers ﬂanking exon 3
(Forward 50-TGTCATGCCAAGGAG-30, Reverse 50-
GATAAGATGGTTGCCAG-30) of the KCNK18 gene containing
the F139FsX39 mutation and the amplicon Sanger sequenced.
IPSCs were cultured in feeder-free conditions on growth-
factor-reduced Matrigel (Corning)-coated tissue culture
dishes, and fed daily with mTeSR1 (StemCell Technologies).
Cells were passaged as patches every 4–7 days, upon reaching
80–95% conﬂuency, using 0.5 mM EDTA in phosphate-buf-
fered saline (PBS, Life Technologies).
Generation of isogenic human TRESK
iPSC lines with CRISPR/Cas9
gene-editing technology
For targeting KCNK18 by CRISPR/Cas9 we designed two
guide RNAs (gRNAs) in http://crispr.mit.edu to target the
F139WfsX24 mutant allele of KCNK18 (KCNK18 px462#
TRESK1 50-ACTTGCCAAGCCTGGTGACGGGG-30 and
KCNK18 px642TRESK#2 50-TGTGCATGCTCTATGCTCTT
TGG-30) using a paired nickase strategy (Ran et al., 2013).
Guides were cloned into the dual Cas9 and gRNA-expressing,
puromycin-resistant pX462 plasmid (Addgene #48141, a kind
gift of F. Zhang).
For gene editing at the F139WfsX24 locus, iPSCs from mi-
graine line 839 were passaged in to single cells and 106 iPSCs
were electroporated (1000 V, 40-ms pulse width, one pulse)
with 5mg of both donor plasmids using Neon (Invitrogen)
and 1 ml of 10 mM single stranded oligonucleotide donor
(ssODN) template of wild-type TRESK containing 100 bp
arms ﬂanking either side of the F139WfsX24 mutation
(Ultramer, IDT technologies). After electroporation, iPSCs
were plated at high density (5  105 cells/cm2). At 1 day
post-transfection, puromycin (1 mg/ml, Life Technologies) selec-
tion was performed for 48 h, and surviving iPSCs were subse-
quently plated at low density onto mitotically-inactivated
mouse embryonic feeder [MEF from CF1 mice (Millipore)];
cells on gelatin-coated tissue culture plates in human embryonic
stem cell medium [KnockOut DMEM, 2 mmol/l L-glutamine,
100 mmol/l non-essential amino acids, 20% serum replace-
ment, and 8 ng/ml basic ﬁbroblastic growth factor (FGF2)].
Individual colonies were manually selected for expansion and
converted to growth on Matrigel in mTeSRTM1. Genomic
DNA was isolated, and colonies genotyped using KCNK18-spe-
ciﬁc PCR primers (above) and Sanger sequencing to conﬁrm
correction of F319WfsX24 mutation to the wild-type sequence.
The CRISPR correction introduced a silent mutation p(Prol142)
3 bp downstream. Gene edited lines were assessed and analysed
using KaryoStudio and GenomeStudio software. SNP devi-
ations in iPSC lines were compared to parent ﬁbroblast pools.
Nociceptor differentiation
IPSC-derived nociceptors were generated using previously pub-
lished protocols (Chambers et al., 2012). Brieﬂy, iPSCs were
treated with accutase to produce single cells plated at a density
of 40 000 cells/cm2 and plated with the Rho-kinase inhibitor
Y-27632 (10 mmol/l; Abcam). Neuralization was initiated
when iPSCs were conﬂuent using MEF-conditioned KSR
media (Knockout DMEM, 15% knockout serum replacement,
1% non-essential amino acids, 1% GlutaMAXTM, 1% peni-
cillin/streptomycin and 100 mM b-mercaptoethanol) media
supplemented with 100 nM LDN-193189 and 10 mM
SB431542 to inhibit SMAD signalling. Cells were fed daily
and N2 media (Neurobasal medium, N2 supplement, B-
27TM supplement without vitamin A, GlutaMAXTM, penicil-
lin/streptomycin) added in 25% increments every other day
starting on Day 4. Supplementation of three inhibitors, 3
mM CHIR99021, 10 mM SU5402 and 10 mM DAPT, on
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Days 2–10 initiated nociceptor induction. On Day 12 cells
were treated with accutase, replated as single cells and main-
tained in long-term culture in N2 media supplemented with
human-b-NGF (25 ng/ml), BDNF (20 ng/ml) and GDNF (20
ng/ml) to promote maturation. The differentiated nociceptors
were cultured for an additional 50 days before functional
assays were performed. For each experiment, iPSCs were inde-
pendently differentiated into nociceptors at least three times
Electrophysiology
Coverslips containing iPSC-derived nociceptors were placed in
a recording chamber mounted onto the stage of an upright
microscope and the soma were targeted for. Cells were con-
tinuously superfused with oxygenated artiﬁcial CSF (95% O2/
5% CO2) containing 140 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 1.2 mM MgCl2, 10 mM HEPES and 10 mM glucose
(pH 7.3). Patch-clamp electrodes (4–7 M) were ﬁlled with an
intracellular solution containing 130 mM KCl, 1 mM MgCl2,
5 mM MgATP, 10 mM HEPES and 0.5 mM EGTA; pH 7.3.
Recordings were obtained using a Multiclamp 700B ampliﬁer
and digitized at 10–20 kHz using Digidata 1550 acquisition
board and data analysed with Clampﬁt 10 (Molecular
Devices). Cell capacitance was compensated for by the cir-
cuitry of the ampliﬁer and series resistance was compensated
60–80% to reduce voltage errors. Upon establishing whole-cell
access, baseline biophysical properties such as cell capacitance,
resting membrane resistance and input resistance were mea-
sured and monitored throughout. Cells were abandoned if
values exceeded 50 mV. Sodium and potassium currents
were evoked by voltage steps ranging from 80 to +50 mV
in 10-mV increments. For current-clamp recordings, voltage
responses were evoked from a holding potential of 60 mV
using 50-ms steps ranging from 0 to +400 pA in 10-pA inter-
vals, until an action potential was elicited. Repetitive ﬁring was
deﬁned as those cells ﬁring more than one action potential to a
prolonged (500 ms) supra-threshold depolarizing current injec-
tion (twice the rheobase current). The experimenter was not
blinded to genotype for patch clamp experiments.
TPA inhibition of TRESK
We used a previously reported ramp protocol to dissect TRESK
currents (Dobler et al., 2007; Liu et al., 2013). In voltage-clamp,
nociceptors were held at 60mV before depolarization to 25
mV for 300 ms and then subsequently ramped to 135mV
over 550 ms. Outward currents were measured at the end of
the 300-ms step. Baseline measurements were collected in the
presence of 1 mM tetrodotoxin (TTX) and subsequently noci-
ceptors perfused with 500 nM tetrapentylammonium bromide
(TPA, Sigma 241970) in the presence of TTX for 20 min before
reassessing TRESK currents.
Multi-electrode array culture
IPSC lines were differentiated to nociceptors and plated on
Matrigel-coated MEA (multi-electrode array) plates
(Cytoview MEA 48, Axion Biosystems) at Day 12 post-induc-
tion with dotting technique at density of 156 000/cm2. At Day
14 the DRG culture was treated for 24 h with 4 mM Cytosine-
b-arabinofuranoside (C1768, Sigma). At Day 16, 52 000/cm2
rat astrocytes (N7745-100, Thermo Fisher) were added to the
culture to support neuronal health and attachment. The rat
astrocyte co-culture does not interfere with the neuronal prop-
erties that we measured (Supplementary Fig. 2), although an
extensive characterization with and without astrocytes was not
performed. Half of the growth media in the culture was chan-
ged every 2 to 3 days, supplemented with laminin (L2020,
Sigma, 1:1000 dilution) once a week. MEA cultures were
kept at 37C and 5% CO2 level. The effects of cloxyquin
and TPA were investigated on Days 60–65 of SCN9A
(Nav1.7) IPSC-derived nociceptors with replicates of six wells
for a single condition.
For MEA recordings, 2-min recordings were taken after 5-
min plate settling time on the MEA reader. The plate was kept
at 37C while recordings were taken. For drug incubation ex-
periment, activity was recorded for 2 min as baseline before
cloxyquin and TPA were added sequentially. Drug experiments
were performed at time points where the spontaneous activity
was stable for at least 3 h before experiment.
Multi-electrode array data analysis
Mean ﬁring rates were calculated using AxIs software (Axion
Biosystems). MEA records the extracellular spiking activity of
neurons. Spikes were detected online by AxIS spike detector
software as described previously (McConnell et al., 2012) and
were deﬁned as an event with amplitude 46 standard devi-
ations (SD) above background noise. Single-electrode bursts
were deﬁned as at least ﬁve consecutive spikes with an inter-
spike interval 5100 ms. Following recording, spike sorting
was performed using the AxISmetrics plotting tool (Axion
Biosystems). Raster plots with histograms were plotted with
NeuralMetric Tools. Raw data scatter plot and percentage
change analysis was performed with custom built program in
MATLAB using mean ﬁring rate information extracted from
raw data from AxIS. In the analysis of drug effect graph, after
excluding inactive electrodes (55 spikes/s), all data from elec-
trodes from the six-well replicates of a condition was pooled
together. Electrodes with ﬁring frequency that fell in-between
25th and 75th percentile in the baseline reading before drug
application were used for analysing effects post drug-addition.
Immunocytochemistry
IPSC-derived nociceptors were ﬁxed with 4% paraformalde-
hyde-PBS for 20 min, washed, permeabilized with 0.1%
TritonTM X-100 and incubated with blocking solution for
1 h at room temperature. Cells were subsequently incubated
overnight at 4C with antibodies to pluripotency (anti-Oct4,
1:200, ab19857), neural crest (p75NTR, 1:100, Promega,
G323A) and neuronal markers (anti-TUJ1, 1:500, MMS-
435P, Covance; anti-Islet-1, 1:100, DSHB-394D5.s; anti-Ret,
1:100, Alamone; and anti-TRESK 1:100 sc-51238 Santa Cruz).
Cells were washed, and incubated with Alexa Fluor 488/568
conjugated antibodies (Life Technologies) for 1 h. Nuclei were
stained with DAPI and ﬂuorescence visualized using confocal
microscopy with a Zeiss 880 inverted microscope.
Efﬁciency of neuronal differentiation was assessed by count-
ing the number of TUJ1+ neuronal cells expressing sensory
neuronal marker Islet-1 and Brn3a. Immunocytochemistry
TRESK expression was analysed measuring the pixel intensity
counted using ImageJ software.
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Immunoblotting
For cell surface expression studies, iPSC-derived nociceptors
were grown in 6 cm2 dishes. On Day 50 cells were washed,
solubilized in fractionation buffer (20 mM HEPES, 10 mM
KCl, 2 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT and protease inhibitors), and passed through a 27G
needle. Samples were centrifuged (3000 rpm and subsequently
8000 rpm) and cytoplasm and mitochondria fractions dis-
carded. The membrane fraction was collected by centrifuging
the sample at 40 000 rpm. Equal amounts of SDS sample
buffer were added and 10 mg samples were resolved on a
Tris-glycine (3–8%) gel (NuPAGE, Invitrogen). Western blots
were blocked (5% milk in 1% PBS-Tween) and probed with a
polyclonal TRESK antibody (sc-51238 P-19, SantaCruz) over-
night. Antibody to the transferrin receptor (1:500, 13-6800,
Invitrogen) was used as a cell surface fraction loading control
followed by anti- rabbit and anti-mouse HRP-conjugated sec-
ondary antibodies (1:2000, P0448 and P0447 DAKO) and
visualized using ECL (Pierce #32106).
Quantitative RT-PCR
Total RNA from cultured cells was extracted using an RNeasy
Mini kit (Qiagen) and 300 ng of RNA was reverse-transcribed
using SuperScriptTM II (Invitrogen). Quantitative PCR was per-
formed by reverse transcription with SYBR Green PCR Master
Mix (Invitrogen) using an Applied Biosystems 7500 Real-Time
qPCR machine. Gene expression is reported as relative quantities
using the CT method. All gene expression values were nor-
malized to the housekeeping gene, GAPDH. Gene expression pri-
mers were as follows: MET/c-Met (F primer 50-ACCTTTGATAT
AACTGTTTACTTGTTGCA-30, R primer 50-GCTTTAGGGTGC
CAGCATTTT-30); RUNX1 (F primer 50-CAAGACCCTGCCCAT
CGCTT-30, R primer 50-GTAGTTTTCATCATTGCCAGCC-30);
KCNK18/TRESK (F primer 50-GTGTTCAGCACCGTGGGCTA-
30, R primer 50-CCGTGAGAACGAGGAACATCA-30); and
GAPDH (F primer 50-AGCCACATCGCTCAGACAC-30, R
primer 50-GCCCAATACGACCAAATCT-30).
Animals
Two- to four-month-old mice on a C57BL/6J background
(Charles River, UK) were allocated to treatment groups by ran-
domly drawing them from their cages and rehousing post-treat-
ment in mixed treatment cages. Sample sizes for the different
behavioural outcomes were based on previous literature, seeking
to observe a 25% change, whereby experiments were performed
with a group size of 5–12 animals (Pradhan et al., 2014; Farkas
et al., 2016; Tipton et al., 2016). TRESK knockout mice were
compared to littermate wild-type mice in all studies. TRESK
knockout animals were generated by the trans-NIH Knock-Out
Mouse Project (KOMP, www.komp.org). In brief, the VelociGene
targeting system was used to ablate Kcnk18 by replacing the
majority of the coding region with a LacZ-neomycin cassette.
Nitroglycerine mouse model
GTN (Hameln) was prepared for injection as a 1 mg/ml solu-
tion reconstituted in saline and injected following baseline be-
havioural testing and 2 h prior to repeat testing. Cloxyquin
(Sigma) was reconstituted in 3.6% DMSO in DPBS and given
at 10 mg/kg and 50 mg/kg as intraperitoneal injections at the
same time as GTN. Control animals received the appropriate
vehicle (saline or 3.6% DMSO in DPBS) in all comparative
behavioural tests.
Von-Frey
Static mechanical thresholds in freely moving awake mice were
examined via von Frey hair application (0.008–1g; Touch TestTM
Stoelting) to the plantar surface of the hindpaw using the ‘up–
down’ method (Chaplan et al., 1994). Before testing, mice were
randomly assigned in to individual plexiglass cubicles (8  5 
10 cm) for 1 h on an elevated wire mesh ﬂoor to enable access to
the paw surface. Calibrated von Frey hairs were applied to the
left and right hind paws, starting with the 0.6g ﬁlament until the
ﬁbre bowed. A positive withdrawal response is followed by a
lower force hair and vice versa for a negative withdrawal re-
sponse until a change in behaviour occurs. Using this up–down
sequence, four subsequent hairs were assessed and the 50% paw-
withdrawal threshold was calculated as described by Dixon
(1980). Data presented are from both left and right hind paws
averaged together as no laterality effects were observed.
Hargreaves
Thermal thresholds in freely-moving awake mice were assessed
with the Hargreaves method using the plantar test (37370,
Ugo Basile). Before testing, mice were assigned to testing cu-
bicles at random and habituated to the apparatus for 1 h in
individual cubicles (8  5  10 cm) placed on a glass plate.
An infrared light source was applied to the plantar surface of
hindpaws through the glass plate. Withdrawal reﬂexes were
recorded from both left and right paws, on three occasions,
leaving at least 2 min between stimuli.
Hot plate
Noxious-thermal thresholds of the hindpaws were examined
via the hot plate test using an incremental hot/cold plate
(35150, Ugo Basile) set at a temperature of 50 and 53C 
0.2C. Mice were placed in the centre of the hot plate in a 10-
cm diameter testing box; licking, jumping or stamping reﬂex
responses were recorded to the nearest 0.01 s. A maximum
latency of 20 s was permitted to prevent tissue damage.
Orofacial pain stimulation testing
Mice were placed in a 15–30 g head access restraining cylinder
(Stoelting Co.) and acclimatized for 5–10 min. The restrainer
allowed access to the head through various holes, with minimal
ability for the mouse to move. Testing began when the mouse
stopped exploring the cylinder. A von Frey ﬁlament of 0.4g
force was applied to the periorbital region, until the ﬁlament
bent (Farkas et al., 2016). The ﬁlament was applied three times
and responses were recorded using a descriptive scoring system
as follows: no response (0 point), mild response: gentle head
shake/ forepaw swipe (0.25 points), moderate response: vigor-
ous head shake/aggression to ﬁlament (0.50) and obvious re-
sponse: complete withdrawal of the head (1 point). The points
were combined to give a complete orofacial pain response score
whereby a score of 3 is the highest response to record.
Statistical analysis for animal studies
The effect of an acute single GTN dose was assessed using an
unpaired t-test, or repeated measures one-way ANOVA
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followed by a Tukey’s multiple comparisons test in Prism
(GraphPad). For analysis of baseline trends in sensory re-
sponses and comparison of sensory responses between wild-
type and TRESK knockout after repeated GTN injections, a
two-way ANOVA with Tukey’s multiple comparisons test was
used. P-values of 50.05 were considered signiﬁcant in all tests.
The operator was blind to genotype and treatment when per-
forming the assays.
Data availability
Raw data were generated at the NDCN, University of Oxford.
Derived data supporting the ﬁndings of this study are available
from the corresponding author on request.
Results
Exome analysis of KCNK18
F139WfsX24 patients
The original ﬁnding of a KCNK18 frameshift mutation in a
migraine pedigree supported by genome-wide signiﬁcant link-
age for the region containing KCNK18, held promise that a
rare variant cause of typical migraine had been identiﬁed. The
original linkage region was located on chromosome 10q25.2-3
and as the linkage region was broad, several other genes could
also explain the linkage signal. To investigate this further, in
three affected individuals from the KCNK18 F139WfsX24
family, whole exome sequencing was performed with an aver-
age 100-fold coverage per exome. This identiﬁed 41 exonic
SNPs, three exonic indels and four exonic substitutions
shared by all three individuals in the linkage region. The
F139WfsX24 mutation in KCNK18 was found in all three
affected individuals. Using an established statistical-based
method for frequency-based ﬁltering of candidate monogenic
disease-causing variants, which accounts for disease prevalence,
genetic and allelic heterogeneity, inheritance mode and pene-
trance, we calculated an expected maximum allele frequency in
the general population for a potential disease-causing migraine
variant (0.7%) (Whifﬁn et al., 2017). Of the variants identiﬁed
in the linkage region by exome sequencing only the
F139WfsX24 KCNK18 mutation was found at a lower fre-
quency than this threshold in the ExAC cohort. This indicates
that the F139WfsX24 KCNK18 mutation is most likely re-
sponsible for the genetic linkage in this family.
TRESK F139WfsX24 and control
pluripotent stem lines
differentiate efficiently into mature
non-peptidergic nociceptors
After establishing that the KCNK18 frameshift mutation
was likely to be responsible for the genetic linkage in this
family, we sought to investigate whether the mutation
would lead to changes in human cellular physiology rele-
vant to migraine headache susceptibility. While the cellular
mechanisms of migraine remain poorly understood, head-
ache arises from activation of nociceptive neurons of the
trigeminal ganglion that innervate dural blood vessels.
We therefore used a previously reported method to produce
functionally mature human peripheral nociceptors
(Chambers et al., 2012). We generated iPSC lines from
dermal ﬁbroblasts using non-integrating Sendai virus from
three related migraine with aura patients with the TRESK
F139WfsX24 mutation and compared them to three unre-
lated healthy control subjects (Hartﬁeld et al., 2014;
Handel et al., 2016) who had not reported a signiﬁcant
headache disorder (Supplementary Table 1). We conﬁrmed
successful reprogramming by immunostaining for pluripo-
tency markers NANOG and OCT-4, and genomic integrity
by SNP karyotyping (Supplementary Fig. 1).
IPSC lines were differentiated into peripheral nociceptors by
dual SMAD inhibition for neuralization, followed by GSK3b,
VEGF and Notch inhibition for neural induction and subse-
quently matured with growth factors NGF, GDNF and
BDNF for 60 days to result in homogenous cultures of elec-
trophysiologically mature nociceptors (Fig. 1). As the cells
differentiated there was progressive loss of pluripotency mar-
kers OCT-4 and acquisition of neural crest marker P75NTR
by Day 8 (Fig. 1A and B). Maturation resulted in pure popu-
lations of Brn3a+ sensory neurons (Fig. 1C). Through early
differentiation, c-Met was transiently expressed while expres-
sion of the transcription factor RUNX1 was delayed but sus-
tained, consistent with in vivo development of non-peptidergic
nociceptors (Fig. 1D). Furthermore, neurons strongly ex-
pressed the non-peptidergic marker, Ret at Day 50 (Fig. 1E).
KCNK18 mRNA expression was absent in iPSC but steadily
increased during nociceptor differentiation and maturation
(Fig. 1F). All lines differentiated efﬁciently into nociceptors,
yielding 24–49% of neurons expressing Islet-1 at Day 14 in
culture (Supplementary Fig. 1F). There were no signiﬁcant dif-
ferences in yield between the iPSC lines, and all of them were
able to ﬁre action potentials reliably and displayed intrinsic
neuronal properties of mature neurons (Fig. 1G and H).
TRESK F139WfsX24 nociceptors
show increased neuronal excitability
associated with a loss of TRESK
function
Patch clamp recordings demonstrated a reduced rheobase of
TRESK F139WfsX24 nociceptors compared to control
(F139wfsX24 101  5.5 pA versus healthy control 158 
3.4 pA), indicative of hyperexcitability (Fig. 2A and B).
Furthermore, injecting a suprathreshold stimulus, the healthy
control neurons typically ﬁred a single action potential,
whereas 56% of TRESK F139WfsX24 neurons ﬁred repeti-
tively (Fig. 3A, P 5 0.0001 Fisher’s exact test). TRESK
F139WfsX24 nociceptors also ﬁred a greater number of
action potentials to suprathreshold stimuli (Fig. 3B).
Comparing the two groups, there were no signiﬁcant differ-
ences in the resting membrane potential (RMP) (healthy
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control 58.79  0.89 mV, F139WfsX24 58.16  1.00
mV, P 4 0.05 student’s unpaired t-test) or input resistance
(healthy control 258.38  14.79 M, F139WfsX24 260.26
 9.12M, P 4 0.05 student’s unpaired t-test). We cultured
healthy control and TRESK F139WfsX24 nociceptors on an
MEA platform to investigate population neuronal activity. We
found no difference in absolute ﬁring frequency, but a signiﬁ-
cant increase in the frequency of burst activity events (at least
ﬁve consecutive spikes with an interspike interval 5100 ms)
comparing the frameshift mutant and the control (P 5 0.001,
Supplementary Fig. 3). These data suggest that F139WfsX24
nociceptors are more likely to repetitively ﬁre multiple action
Figure 1 Differentiation of nociceptors from iPSCs. (A) Representative image of iPSC line losing the pluripotency marker, OCT-4
expression during nociceptor differentiation. Scale bar = 200 mm. (B) Widespread protein expression of the neural crest marker p75(NTR) at
Day 8. (C) Representative images illustrating the presence of neuronal (TUJ1) and sensory (Brn3a) markers in mature neurons after 50 days in
culture. (D) Quantitative RT-PCR analysis indicates a progressive increase in RUNX1 expression with a corresponding decline in MET/c-Met
indicating acquisition of non-peptidergic nociceptor fate. Gene expression levels were normalized to GAPDH and are presented as values relative
to a sample of undifferentiated iPSC (i.e. Day 0). (E) Expression of the non-peptidergic marker, RET, in mature neurons. (F) RT-qPCR detection of
KCNK18 (TRESK) mRNA transcript level increases as nociceptors mature (P 4 0 .05, one-way ANOVA). GAPDH expression was used as a
housekeeping gene to normalize expression levels. (G) Whole cell recording of single action potentials can be evoked reliably in both control
nociceptors and F139WfsX24 nociceptor lines. (H) Representative voltage clamp data showing inward and outward currents recorded during
step membrane depolarization of control wild-type (AH017-7) and F139WfsX2 (839) nociceptors. Unless otherwise stated, scale bars = 50 mm.
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potentials once activated and are therefore congruous with the
hyperexcitability observed by patch clamp recordings.
To investigate further the mechanisms by which the
TRESK F139WfsX24 nociceptors have heightened
excitability, we analysed the expression of TRESK
(Fig. 2C–E). We used an antibody targeting amino acid resi-
dues 200–250 in the large intracellular loop (not translated in
the F139WfsX24 mutant allele) to demonstrate a 50%
Figure 2 Comparison of control and F139WfsX24 mature iPSC-derived nociceptors. (A) Representative current clamp traces, showing
subthreshold responses and subsequent action potentials evoked until reaching current threshold (rheobase) of 220 pA for wild-type (NHDF-1) and
90 pA for F139WfsX24 cells (Line 839). (B) All three cell lines carrying the F139WfsX24 mutation required significantly lower rheobase than wild-type
(one-way ANOVA, n total = 298, P 5 0.0001, mean rheobase  SEM: wild-type 158 pA  7.4; F139WfsX24 line 837 111.5 pA  8.2; line 838
109 pA  12.5; line 839 83.4 pA  8.7) (C) Representative images illustrating the presence of TRESK in Day 50 iPSC-derived nociceptors from wild-
type or F139WfsX24 lines (D). Image intensity analysis showed reduced TRESK expression in F139WfsX24 migraine nociceptors (Mann-Whitney test,
P 5 0.0001). TRESK was present in cell lysate surface membrane fractions of wild-type nociceptors, but absent in F139WfsX24 nociceptors by
western blot (E). b-Transferrin (b-TF) was used as a loading control. (F) F139WfsX24 migraine nociceptors had reduced potassium leak current
compared to wild-type, Mann-Whitney test P = 0.0471. Boxplot 5-95 percentiles. (G) Treatment of mouse primary DRG cultures with TRESK
inhibitor, 0.5 mM TPA, selectively blocks potassium leak current in wild-type DRG cultures, but has no effect on DRG cultures from TRESK knock-out
mice. (H). Similarly, 0.5mM TPA has no effect in F139WfsX24 migrane neurons (paired t-test, mean reduction; wild-type nociceptors 23%;
F139WfsX24 nociceptors 2.4%). Boxplot 5 - 95 percentiles. DRG = dorsal root ganglia.
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reduction in protein by immunocytochemistry in TRESK
F139WfsX24 nociceptors, consistent with the heterozygous
nature of F139WfsX24 (Fig. 2D). In addition to a global
reduction, we noted that TRESK protein was predominantly
cytoplasmic in TRESK F139WfsX24 nociceptors and not
localized with the membrane (Fig. 2C). To assess membrane
Figure 3 F139WfsX24 causes neuronal hyperexcitability in iPSC-derived nociceptors. (A) Injecting a suprathreshold current into
neurons resulted in increased repetitive firing in F139WfsX24 lines (56% versus controls 26%, Fisher’s exact test P 5 0.0001). Representative
trace from NHDF-1 (control) and 839 (F139WfsX24) (B) The number of action potentials generated from a suprathreshold stimulus (2
rheobase) were quantified and observed to be significantly higher in all three F139WfsX24 migraine iPSC nociceptors (one-way ANOVA, P 5
0.001, n = 136). (C) IPSC lines were reprogrammed from erythroblasts from subjects with the C110R variant (8152) or wild-type (BPC345) and
compared to fibroblast derived iPSC from wild-type (AH017-7) or F139WfsX24 (839). The F139WfsX24 nociceptors show a significantly
reduced rheobase compared to wild-type or C110R variant nociceptors. (D) The C110R nociceptors did not fire repetitively to a suprathreshold
stimulus unlike the F139WfsX24 nociceptors and (E) TPA was able to inhibit outward leak current in wild-type (19.13%) and C110R (33.46%)
nociceptors, but had minimal effect in the F139WfsX24 nociceptors. (F) F139WfsX24 iPSC line (839) was genome ‘corrected’ to the wild-type
allele and TRESK expression recovered to wild-type levels [Kruksal-Wallis test P = 0.004, Dunn’s multiple comparisons test: wild-type versus
F139WfsX24 P = 0.0009, wild-type versus correction, not significant (ns), F139WfsX24 versus correction P = 0.0103]. Boxplot 5–95 percentiles.
(G) Genome-corrected iPSC neurons, reversed rheobase to wild-type levels (one-way ANOVA P5 0.0001; Dunn’s multiple comparisons; wild-
type versus parent F139WfsX24 P 5 0.0001, wild-type versus corrected ns, corrected versus parent F139WfsX24 P 5 0.05). (H) Increasing
suprathreshold current injection, induces a progressive increase in the number of action potentials fired by parent F139WfsX24-nociceptors
compared to both wild-type and genome corrected clone (one-way ANOVA, P = 0.0099, with Sidaks multiple comparison wild-type versus
parent F139WfsX24 P 5 0.001, wild-type versus corrected ns, corrected versus parent F139WfsX24 P 5 0.05). Data represent mean  SEM
pooled from three independent differentiations.
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expression, we performed a membrane preparation of iPSC
nociceptors and a western blot for TRESK expression. We
found that wild-type TRESK protein was absent in mem-
brane fractions of F139WfsX24 nociceptors, but detectable
in the healthy control (Fig. 2E and Supplementary Fig. 4).
Hence the mutant channel appears to be exerting a dominant
negative effect on wild-type channel to prevent wild-type
channel membrane expression.
Voltage clamp recordings conﬁrmed a functional reduc-
tion of leak potassium current in F139WfsX24 nociceptors
(Fig. 2F). There was still a substantial leak current in
F139WfsX24 nociceptors indicating the presence of other
K2P channels. To isolate the TRESK component, we have
previously used TPA applied extracellularly at 0.5 mM to
selectively inhibit TRESK (Wright et al., 2013). At this
concentration, in mouse primary trigeminal ganglion
neurons, we found that TPA reduces the leak current in
wild-type trigeminal ganglion neurons but has no effect
on trigeminal ganglion neurons with TRESK genetically
ablated, indicating a selective effect of TPA (Fig. 2G).
TPA had no effect on the activity of another key K2P chan-
nel, TREK-1, when expressed in HEK cells (Supplementary
Fig. 5). We found that TPA reduced the leak current in
healthy control cells, but had no effect on F139WfsX24
nociceptors (healthy controls 22.98  10.14% versus
F139WfsX24 2.41  5.9%, P = 0.0068 Wilcoxon
matched-pairs) (Fig. 2H).
TRESK C110R nociceptors do not
show increased neuronal excitability
The C110R mutation has previously been shown to have a
dominant negative effect, with a profound loss of TRESK
current in Xenopus oocytes (Andres-Enguix et al., 2012).
We therefore obtained erythroblasts from a blood sample
from a non-headache subject with the C110R mutation and
reprogrammed to iPSCs using Sendai virus.
Reprogramming from adult cells to iPSCs is thought to
clear the epigenetic memory and have little inﬂuence on
the subsequent phenotypes of the differentiated cells
(Rouhani et al., 2014). However, as the previous iPSC
lines were generated from dermal ﬁbroblasts, we also
reprogrammed erythroblasts from a healthy control subject
without the C110R variant to have comparable controls.
Despite the previous study indicating that C110R mutations
leads to loss of function, we found C110R nociceptors to
have excitability measures comparable to the healthy control
nociceptors, as assessed by rheobase and the number of
action potentials ﬁred upon a supra-threshold stimulus,
whether derived from erythroblasts or dermal ﬁbroblasts
(Fig. 3C–E). The TRESK F139WfsX24 nociceptors had sig-
niﬁcantly reduced excitability compared to erythroblast
C110R nociceptors as indicated by the rheobase and
number of action potentials ﬁred upon a suprathreshold
stimulus (Fig. 3C) (F139WfsX24 92.3  10.5 pA versus
C110R 291.9  27.4 pA, P = 0.0002, one-way ANOVA
followed by Tukey’s multiple comparison) and number of
action potentials ﬁred (Fig. 3D, P = 0.0476, Fisher’s exact
test; F139WfsX24 repetitive ﬁring 80%; control repetitive
ﬁring 20%). Furthermore, the proportion of the leak current
inhibited by 0.5 mM TPA in C110R nociceptors was compar-
able to control (Fig. 3E) [mean reduction  SEM; wild-type
(ﬁbroblast) 19.13%  1.267, wild-type (erythroblast)
19.43%  3.769, C110R 33.46%  3.265, and
F139WfsX24 3.14%  1.9. P = 0.0055 one-way ANOVA
followed by Kruskal-Wallis test].
The TRESK F139WfsX24 mutation
increases nociceptor excitability
To provide more evidence for a role of F139WfsX24 in
altering neuronal excitability, we used CRISPR-Cas9
genome engineering to correct the mutation back to the
wild-type sequence (Supplementary Fig. 6). We conﬁrmed
that there were no signiﬁcant karyotypic abnormalities
after cloning and expanding the corrected clone. The ex-
pression level of TRESK in nociceptors was restored to
control levels (Fig. 3F, one-way ANOVA P = 0.004).
Genome corrected iPSC nociceptors had signiﬁcantly
reduced nociceptor excitability as demonstrated by a
reduced rheobase (one-way ANOVA P = 0.03, Dunnett’s
multiple comparisons test, Fig. 3G) and reduced propensity
to ﬁre repeatedly to a supra-threshold stimuli (Fig. 3H, one-
way ANOVA, P 5 0.05) compared to F139WfsX24 parent
clone nociceptors (line 839). Interestingly we observed that
injection of current between 150 and 300 pA, had the max-
imal effect in generating repetitive action potentials in
F139WfsX24 nociceptors with signiﬁcant differences in
this range to both the genome corrected line and the
wild-type line. The reversal of the excitability phenotype
suggests that the F139WfsX24 mutation is responsible for
heightened nociceptor excitability.
The TRESK activator, cloxyquin,
reduces spontaneous nociceptor
firing of an in vitro pain model
The voltage gated sodium channel Nav1.7, is considered a
threshold channel, boosting depolarizing inputs to reach
the action potential threshold. We reasoned that TRESK
should act in an opposite manner to Nav1.7, to dampen
rather than boost depolarizing inputs. We therefore estab-
lished an MEA-based assay to investigate whether a known
TRESK activator, cloxyquin, was able to reverse an in vitro
pain cellular phenotype. We used the iPSC line RCi002-A,
which is derived from a patient with inherited erythrome-
lalgia (IEM) and carries the F1449V gain-of-function mu-
tation in Nav1.7, and has previously been demonstrated to
exhibit spontaneous ﬁring when differentiated into nocicep-
tors (Cao et al., 2016).
RCi002 was patterned towards nociceptors, plated onto
multi-well MEA plates as a co-culture with rat astrocytes
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Figure 4 MEA data of iPSC nociceptors. (A) Representative image of density and spread of nociceptors on the electrodes in a well of 48
well MEA plate. (B) Recorded mean firing rate of SCN9A (Nav1.7) gain of function mutation iPSC nociceptors (n = 6) from Days 19 to 50 of the
differentiation. Inset shows a representative raster plot and histogram of spontaneous activity of nociceptors. Each line represents recorded spike
timings per electrode in the well, and the histogram at the top of the raster plot represents the sum of spiking activity. (C) Recorded mean firing
rate of healthy control iPSC nociceptors (n = 6) from Days 18 to 50 of the differentiation. Inset shows a representative raster plot and histogram
of spontaneous activity of nociceptors in a well of the plate at D50 (D–F) raster plot with histogram of spontaneous action potentials recorded in
a representative well of the MEA plate. (D) Nav1.7 nociceptor response before cloxyquin. (E) Nav1.7 nociceptor response to 50 mM cloxyquin (in
0.01% DMSO); (F) Nav1.7 nociceptor response to 50 mM cloxyquin (in 0.01% DMSO) with 0.5 mM TPA. (G) Percentage change in firing rate of
nociceptors in response to increasing dose of cloxyquin. Reversal of inhibition by subsequent addition of 0.5 mM TPA is observed. One-way
ANOVA multiple comparison: P 5 0.05; P 5 0.001; P 5 0.0001).
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and then matured for 60–70 days (Fig. 4A). The iPSC IEM
mutant Nav1.7 nociceptors and healthy control nociceptors
progressively increased their activity with maturation in
culture. The IEM nociceptors showed sustained spontan-
eous ﬁring, with the majority of electrodes in a well
active and the mean ﬁring rate at 1–3 Hz compared to
the control nociceptors ﬁring of 51 Hz, (Fig. 4B, C and
Supplementary Fig. 7). We then added increasing doses of
cloxyquin and found a signiﬁcant inhibition of ﬁring rate
compared to the DMSO vehicle control [% change 
SEM: 25 mM cloxyquin 35.0%  4.6 (one-way
ANOVA P = 0.0257); 50 mM cloxyquin 47.5%  4.0
(one-way ANOVA P = 0.0006); Fig. 4D–G]. Furthermore,
subsequent addition of 0.5 mM TPA was able to reverse the
cloxyquin effect, conﬁrming that cloxyquin is speciﬁcally
exerting its neuronal dampening through activation of
TRESK.
Cloxyquin is effective in reducing
mechanical and thermal hyperalgesia
in the chronic nitroglycerine model
Having demonstrated the efﬁcacy of cloxyquin in vitro, we
next examined a well-established rodent migraine model
(Pradhan et al., 2014). Chronic intermittent GTN adminis-
tration in rodents induces aversion to light in addition to
thermal and mechanical hypersensitivity; features that are
common among migraineurs. After a single dose of 10 mg/
kg GTN intraperitoneally, wild-type mice developed hind-
paw mechanical and thermal hypersensitivity, which was
reversible with the migraine abortant therapy, sumatriptan
(Supplementary Fig. 8A). To produce a chronic model, we
injected a cohort of animals with GTN daily, and measured
sensitivity on each testing day before each dose (termed
‘baseline’) and 2 h after injection (termed ‘acute’).
Consistent with previous studies we found acute hypersen-
sitivity (mechanical and thermal) following each GTN dose,
in addition to a progressive increase of baseline sensitivity
as treatment continued. Increases in acute sensitivity to
GTN were reversed with the migraine preventative topira-
mate (Supplementary Fig. 8B). We used TRESK knockout
mice, in which the majority of the Kcnk18 coding region
has been removed (Valenzuela et al., 2003), in order to
mimic the complete loss of function conferred by the
F139WfsX24 mutation in an in vivo context and to
assess the contribution of TRESK to hypersensitivity fol-
lowing chronic GTN. Genetic ablation of TRESK did not
alter expression of TREK-1 or TREK-2, two other K2P
channels recently implicated in migraine pathogenesis
(Royal et al., 2019) (Supplementary Fig. 9). TRESK knock-
out mice developed similar baseline hypersensitivity after
chronic GTN (Fig. 5D); however, they exhibited persist-
ently exaggerated mechanical and thermal sensitivity fol-
lowing acute GTN (Fig. 5A). The difference between the
genotypes was diminished (mechanical), or lost (thermal),
at later time points of chronic dosing (Fig. 5A). Consistent
with this ﬁnding, we found that KCNK18 mRNA expres-
sion was signiﬁcantly reduced at a later time point (30%
reduction, P = 0.038; Fig. 5B). We used mechanical testing
of the periorbital facial region to assess orofacial pain be-
haviours following acute GTN. Wild-type and knockout
animals treated with 10 mg/kg GTN both demonstrated
enhanced responses compared to vehicle-treated control
(Fig. 5C). However, following treatment with a lower
dose of GTN (5 mg/kg), only TRESK knockout animals
demonstrated enhanced responses to baseline (Fig. 5C),
demonstrating that mice lacking TRESK have heightened
susceptibility to GTN-induced mechanical sensitization of
the orofacial region.
Wild-type mice treated with 50 mg/kg cloxyquin demon-
strated reduced baseline sensitization after repeated GTN
injections (Fig. 5D). Furthermore 50 mg/kg cloxyquin was
able to completely prevent acute responses to GTN, follow-
ing chronic intermittent GTN administration (Fig. 5E). This
effect was dose dependent, as 10 mg/kg cloxyquin was non-
effective in reducing baseline sensitization and less effective
in preventing acute GTN responses (Fig. 5D and E). In
TRESK knockout mice, cloxyquin had no discernible
effect on baseline sensitization, or the acute sensory hyper-
sensitivity induced by GTN in chronically dosed animals
(Fig. 5D and E). These ﬁndings support the role of
TRESK in migraine development and its potential promise
as an analgesic drug target.
Discussion
The cellular substrates of migraine are poorly understood
but activation of the trigeminovascular system, with trigem-
inal nociceptors innervating dura blood vessels, is likely a
prerequisite for the painful headache phase (Cader, 2013).
Therefore any factor that results in increased excitability of
nociceptors may increase the likelihood of converging pro-
cesses such as cortical spreading depression or other neuro-
genic signals to more easily activate nociceptors and trigger
headaches. TRESK is an important ion channel in nocicep-
tive neurons and we found that human iPSC nociceptors
increasingly express functional TRESK as they mature, sup-
porting an important role for TRESK in the maturation of
intrinsic neuronal properties.
We have shown that the F139WfsX24 frameshift muta-
tion causes hyper-excitability through a dominant negative
effect of the mutant allele on the wild-type to prevent the
wild-type channel from reaching the plasma membrane. It
is possible the truncated protein produced by the frameshift
mutant allele is able to trap the wild-type protein to prevent
trafﬁcking to the membrane. Despite the loss of TRESK
protein and current at the membrane, there is no signiﬁcant
change in the RMP, which is consistent with prior studies
showing TRESK is usually in a closed state at the RMP, so
may not contribute to leak currents that maintain RMP.
Furthermore, it is now appreciated that K2P channels ex-
hibit voltage-dependency (Schewe et al., 2016) and produce
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a large rectifying conductance at subthreshold potentials to
inhibit neuron ﬁring. Additionally, they are responsive to a
range of intracellular signals including G-protein subunits
and uniquely in the case of TRESK, responding to calcium
(Czirjak et al., 2004). Hence an absence of TRESK would
remove the ‘brakes’ from pain initiating signals that acti-
vate nociceptors.
Our ﬁndings that TRESK effectively acts as a brake upon
depolarizing stimuli that may trigger action potential ﬁring
in nociceptors raised the possibility that TRESK activators
could be effective pain therapeutics. Patients with gain of
function mutations in the SCN9A gene, encoding the
voltage gated sodium channel, Nav1.7, have IEM and ex-
perience chronic extreme pain (Dib-Hajj et al., 2005).
Nav1.7 is considered a threshold channel, to boost depolar-
izing inputs below action potential threshold. SCN9A gain-
of-function mutations alter the channel biophysical proper-
ties, such that they are more likely to be activated at hyper-
polarizing potentials and therefore have an increased
liability to ﬁre action potentials. Nociceptors generated
from patients with IEM display increased excitability with
reduced rheobase and increased spontaneous nociceptor
ﬁring and this in vitro phenotype is sensitive to Nav1.7
blockers including a clinical test agent (Cao et al., 2016).
Figure 5 The effect of TRESK loss or activation in the chronic GTN rodent migraine model. (A) TRESK wild-type (WT) (n = 6) and
knockout (KO) (n = 7) littermates were dosed daily for 11 days with 10 mg/kg GTN and mechanical and thermal sensitivity (Hargreaves test and
53C hot plate test) was recorded 2 h post-GTN daily to obtain a measure of acute sensitization [von Frey, two-way ANOVA F(1,14) = 54.97,
P5 0.0001; Hargreaves, two way ANOVA F(1,14) = 74.2, P5 0.0001; hot plate, two-way ANOVA F(1,14) = 29.42, P5 0.0001]. Tukey’s multiple
comparison test P 5 0.001, P 5 0.01, P 5 0.05 TRESK knockout versus TRESK wild-type. (B) Analysis of KCNK18 (TRESK) mRNA
extracted 2 h following 10 mg/kg GTN treatment on Day 1 (acute) and after 11 days of daily GTN injections (chronic). Two-way ANOVA: F(1,4) =
4.459, P = 0.0423; P = 0.038 TRESK knockout versus TRESK wild-type. (C) Effects of acute GTN administration (10 mg/kg or 5 mg/kg i.p.)
compared to vehicle controls in TRESK wild-type versus TRESK knockout mice on orofacial pain testing using 0.4g von Frey filament. Data are
presented as mean  SEM [VEH WT n = 6; VEH KO n = 6; GTN WT (5 mg/kg) n = 17 (10 mg/kg) n = 14; GTN KO (5 mg/kg) n = 7 (10 mg/kg)
n = 7]. P5 0.05; P5 0.001; P5 0.0001 for repeated measures one-way ANOVA with Tukey’s multiple comparison test, boxplot 5–95
percentiles. (D) The TRESK activator cloxyquin dose-dependently reduces baseline sensitization to von Frey filaments [two-way ANOVA: F(3,36)
= 22.89, P5 0.0001; Tukey’s multiple comparison test P5 0.05, GTN+50 mg/kg cloxyquin versus GTN+Vehicle] and Hargreaves test [two-way
ANOVA: F(3,36) = 15.08, P 5 0.0001; Tukey’s multiple comparison test P 5 0.05, GTN+50 mg/kg cloxyquin versus GTN+vehicle] after
repeated intraperitoneal GTN in wild-type mice. No significant differences were observed in TRESK knockout mice treated with cloxyquin. (E)
Sensitivity following acute GTN in chronically sensitized TRESK wild-type mice is significantly attenuated with 10 mg cloxyquin and to a greater
degree with 50 mg cloxyquin [two-way ANOVA von Frey: F(3,36) = 80.57, P5 0.0001; Tukey’s multiple comparison test P5 0.0001, P5
0.001 GTN+50 mg cloxyquin versus GTN+vehicle; ###P5 0.001 ##P5 0.01 #P 5 0.05, GTN+10 mg cloxyquin versus GTN+vehicle; two-way
ANOVA hargreaves: F(3,36) = 76.4, P 5 0.0001; Tukey’s multiple comparison test P 5 0.0001, P 5 0.001, P 5 0.01 GTN+50 mg
cloxyquin versus GTN+vehicle; #P 5 0.05, GTN+10 mg cloxyquin versus GTN+vehicle]. No significant differences were observed in TRESK
knockout mice treated with cloxyquin. wild-type n = 6 and knockout n = 9 for D and E. All data represent mean  SEM. Baseline with GTN
represents daily thresholds taken prior to GTN injection.
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As TRESK is also a ‘threshold’ channel but acts in an op-
posite manner to Nav1.7, TRESK activation should be able
to counter the increased liability to ﬁring action potentials
in the IEM pain model. We used cloxyquin as a TRESK
activator, a drug that we previously identiﬁed from a drug
screen of FDA approved compounds and conﬁrmed that
this led to a reduction in nociceptor ﬁring by 50%.
Cloxyquin selectively activates TRESK and not other K2P
channels (Lengyel et al., 2017). To demonstrate that the
effect of cloxyquin was through TRESK further, we used
the TRESK selective inhibitor, TPA, to show that the clox-
yquin induced reduction in ﬁring was fully reversed by
TRESK blockade.
To build on our ﬁndings at the cellular level, we assessed
the contribution of TRESK to sensitization in an in vivo
migraine mouse model. Given that TRESK is highly en-
riched in the sensory ganglia of rodent and humans
(Lafreniere et al., 2010; Ray et al., 2018), we focused our
efforts on peripheral mechanisms. Mice lacking TRESK
demonstrate exaggerated acute mechanical and thermal
hyperalgesia in response to GTN treatment. These results
are highly congruous with a recent study demonstrating
that TRESK knockout mice exhibit exaggerated nocifensive
behaviours during an inﬂammatory headache model (Guo
et al., 2019). Conversely, cloxyquin can prevent basal and
acute GTN sensitization. Interestingly the effect of cloxy-
quin is evident despite a reduction in KCNK18/TRESK
mRNA expression after chronic GTN treatment.
Nevertheless we conﬁrmed that cloxyquin is mediating its
effects through TRESK, since cloxyquin was completely in-
effective in the TRESK knock-out animals. The ability of
cloxyquin to prevent acute responses to GTN after chronic
sensitization may suggest that novel potent TRESK activa-
tors may remain effective as a migraine treatment in
chronic migraine states. This is an important consideration
since clinical experience is often that in chronic migraine,
patients become refractory to the usual treatments.
Our data also highlight the challenges to investigating
genetic associations between KCNK18 variants and mi-
graine, as any association analysis requires robust selection
of only those mutations that have deleterious effects in
relevant human cells. The genomic background contributes
to excitability and therefore is an important consideration
of mutation penetrance. A recent study highlighted the role
of the polygenic risk burden even in Mendelian-like mi-
graine families (Gormley et al., 2018). The ExAC browser
is also often used to assess whether a variant has popula-
tion characteristics to suggest a pathogenic role such as a
very low allele frequency. However, it may be less useful in
the case of KCNK18 variants because a higher allele fre-
quency may be anticipated for two reasons: (i) a complete
loss of TRESK function has clearly been tolerated in this
family without affecting survival or reproductive ﬁtness, so
deleterious TRESK variants will not be subject to negative
selection pressures; and (ii) the lifetime migraine prevalence
of 15% or more is such that if a KCNK18 mutation was
associated with migraine, individuals with such a mutation
will be in the ExAC cohort at higher frequencies than for
other less prevalent disorders. Unfortunately, migraine
status is not available in ExAC to investigate this further.
The identiﬁcation of the C110R mutation, which shows a
similar dominant loss-of-function to F139WfsX24 in heter-
ologous expression systems and is present in healthy con-
trol subjects, signiﬁcantly undermined the case that TRESK
mutations may be causative of migraine. We found, how-
ever, that in human nociceptors, the C110R mutation had
no loss of TRESK current compared to wild-type controls
and no consequent change in nociceptor excitability. This is
consistent with a previous study where TRESK wild-type,
F139WfsX24 and C110R variants were overexpressed in
primary mouse trigeminal neurons and only F139WfsX24
led to increased neuronal excitability (Guo et al., 2014).
Hence it seems only speciﬁc TRESK mutations are able to
lead to a sufﬁciently large loss of TRESK function in
human nociceptors, presumably through trapping wild-
type channels and preventing membrane expression.
A recently published study describes a second mechanism
by which F139WfsX24 renders nociceptors hyperexcitable
(Royal et al., 2019). Their study and ours complement each
other and strongly support the hypothesis that
F139WfsX24 plays a causal role in migraine pathogenesis.
Royal et al. performed elegant experiments to discover a
second translational start site induced by the frameshift
mutation that results in the production of two transcripts
(termed MT1 and MT2). When overexpressed in heterol-
ogous expression systems MT1 acts in a dominant negative
manner on wild-type TRESK, whereas MT2 does so on
two other K2P channels: TREK-1 and TREK-2. The au-
thors subsequently demonstrate that MT2 is capable of
enhancing trigeminal ganglion excitability and that when
overexpressed in vivo, results in orofacial mechanical
hypersensitivity. Our data are consistent with their ﬁndings
and it is possible that downregulation of TREK-1/2 chan-
nels contributes to the hyperexcitability we observed in
F139WfsX24 iPSC-nociceptors. However, our ﬁnding of
greater inhibition of wild-type TRESK currents by
F139WfsX24 versus C110R TRESK and the phenotype
of TRESK knockout mice treated with GTN, strongly sug-
gest that loss of wild-type TRESK conductance is a major
pathological contributor in itself. TRESK expression is re-
stricted to select populations of trigeminal neurons (Weir
et al., 2019). Future studies should assess TRESK/TREK
co-expression and also whether MT2 expressed at endogen-
ous levels in human nociceptors results in TREK-1/2 inhib-
ition and the relative contribution made by down-
regulation of wild-type TRESK and TREK-1/2 to migraine
pathogenesis. This could be addressed by generating a
F139WfsX24 TRESK knock-in mouse model, or by over-
expressing MT1 and MT2 in TRESK knockout and TREK-
1/2 knockout transgenic mice.
Our data therefore support a genetic role of speciﬁc
TRESK mutations in migraine. Moreover, we also demon-
strate using in vitro and in vivo models that TRESK
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activators are a promising therapeutic approach to pain
and migraine.
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